Wall Street Coverage Shrinks: Only 7 Cannabis Stocks Make the Cut
Analyst coverage in cannabis continues to contract as institutional interest wanes, leaving just seven companies with active Wall Street research coverage.
Wall Street's retreat from cannabis coverage accelerates as institutional analysts abandon coverage of all but seven companies in the sector. The dramatic contraction reflects broader institutional hesitancy around cannabis investments, driven by federal prohibition and limited banking access that continues to constrain traditional finance participation.
The handful of companies maintaining analyst coverage represents a stark reality check for an industry that once commanded significant Wall Street attention during the initial legalization wave. Major multi-state operators like Curaleaf (CURLF), Trulieve (TCNNF), and Green Thumb Industries (GTBIF) likely comprise the core group, given their market capitalizations and institutional accessibility through over-the-counter trading.
This coverage drought creates a feedback loop that further marginalizes cannabis equities in institutional portfolios. Without regular analyst reports, price targets, and research notes, cannabis companies struggle to attract new institutional capital or maintain existing investor interest. The lack of coverage also reduces market efficiency, as fewer professionals track quarterly performance and industry developments.
The contraction coincides with broader challenges facing cannabis operators, including compressed margins from oversupply in mature markets like California and Colorado, plus limited interstate commerce that prevents true scale economics. Companies outside the coverage universe face particular challenges accessing capital markets, often relying on expensive debt financing or dilutive equity raises.
For investors, this coverage gap creates both risk and opportunity. While reduced analyst attention can lead to pricing inefficiencies and higher volatility, it also means less institutional competition for quality assets. The seven companies maintaining coverage likely represent the sector's most financially stable operators with clearest paths to federal legalization benefits, making them potential beneficiaries when broader Wall Street interest eventually returns.